SOTIO Biotech develops immunotherapies for cancer treatment, focusing on advancing safer and effective options through clinical development. The company self-describes as focusing on a broad pipeline addressing various solid tumor types.

SOTIO Biotech

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1; AUTO6NG, a programmed T cell investigational therapy, which is in preclinical trail targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate that is in a Phase I clinical trial for multiple myeloma. It also focuses on developing AUTO5, a hematological product candidate, which is in preclinical development. The company was incorporated in 2014 and is headquartered in London, the United Kingdom.

Martin Pule

Tim Funnell

Autolus Therapeutics plc

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphocytic leukemia (CLL) and multiple sclerosis; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and DuoHexaBody-CD37 for treating hematological malignancies. The company also develops Teclistamab, which is in Phase 2 trial for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. In addition, it has approximately 20 active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with CureVac AG for the research and development of differentiated mRNA-based antibody products; argenx to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology; and AbbVie for the development of epcoritamab, as well as collaborations with BioNTech, Janssen, Novo Nordisk A/S, BliNK Biomedical SAS, and Bolt Biotherapeutics, Inc. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.

Don Drakeman

Jan van de Winkel

Genmab A/S

Imcheck Therapeutics is a biotechnology company developing ICT41, a humanized anti-BTN3A monoclonal antibody that selectively activates γ9Vδ2 T cells to combat infectious diseases.

Imcheck Therapeutics

SOTIO Biotech is developing potent immunotherapies for patients with cancer, focusing on advancing safer and more effective treatments through clinical development.

SOTIO Biotech | 8,879 followers on LinkedIn. Shaping the future of cancer immunotherapies by translating compelling science into patient benefit. | SOTIO Biotech is shaping the future of cancer immunotherapies by translating compelling science into patient benefit. SOTIO’s robust clinical pipeline includes a next-generation PD-1-inhibiting cytokine, a proprietary technology designed to improve on the efficacy of CAR T therapies and a new generation of potent and stable antibody-drug conjugates (ADCs). SOTIO is a member of the PPF Group.

Isabelle Serve

Jens Hennecke

Head of Business Development and Licensing | Pharmaceuticals, Life Sciences

Norbert Prenzel

Roman Kovář

We will present at the American Association for Cancer Research conference on Tumor-body interactions: The Roles of Micro- and Macroenvironment in Cancer in Boston, MA. Šárka Vošahlíková ’s poster will focus on the role of PARP inhibitors for successful immunotherapy in #ovariancancer . #Biotechnology #CancerResearch #jsmePPF

This week, we will attend the Connective Tissue Oncology Society 2024 annual meeting in San Diego. Our Chief Executive Officer, Radek Spisek , Ph.D., and Senior Medical Director, Vivi Boura, MD, PhD , will connect with fellow sarcoma experts and discuss our ongoing efforts in advancing treatments for #sarcoma , such as through our DUET-01 clinical trial studying BOXR1030. #Biotechnology #CancerResearch #jsmePPF

Klára Plačková , junior scientist, is presenting at the INTERNATIONAL PAPILLOMAVIRUS SOCIETY - IPVS Conference in Edinburgh, UK, sharing insights on how tissue structure influences the pattern and density of immune cells that infiltrate tumors in HPV-related cancers. #Biotechnology #CancerResearch #IPVC2024 #jsmePPF

We are presenting a preclinical update on SOT201, a next-generation PD-1-targeting immunocytokine, this week at #SITC24 . New data support SOT201’s ability to reinvigorate exhausted immune cells in PD-1 sensitive and resistant tumor models. SOTIO’s two other posters at Society for Immunotherapy of Cancer (SITC) Annual Meeting provide an overview of the ongoing Ph1 clinical trial of SOT201 (VICTORIA-01) and explore the use of a chimeric PGC-1α transgene to enhance CAR T cell activity. Read more in our press release: https://bit.ly/3As1deT #Biotechnology #cancer #CancerResearch #SITC2024 #jsmePPF

#DidYouKnow that #PancreaticCancer is one of the deadliest cancers, with a 5-year survival rate of just 12%? Our Phase 1/2 CLAUDIO-01 trial is currently evaluating SOT102, a Claudin 18.2 ADC, for the treatment of pancreatic cancer. At SOTIO, we’re committed to changing the landscape of #cancer treatment by advancing innovative therapies that aim to improve the lives of patients battling devastating illnesses like pancreatic cancer. Learn more about SOT102 candidate at: https://bit.ly/48CzAfS #PancreaticCancerAwareness #PCAM #Biotechnology #CancerResearch #jsmePPF

Lung cancer is the most common #cancer in men and the second most common in women. As we observe #LungCancerAwarenessMonth , we reaffirm our dedication to advancing therapies for patients facing this significant unmet medical need. #Biotechnology #CancerResearch #jsmePPF

Next month we will be at the World ADC Event Series conference in San Diego. Martin Steegmaier , Chief Scientific Officer, will present on some of the latest progress in our portfolio of #ADC candidates for solid tumors. If you’re attending, be sure to stop by his presentation, or reach out to connect. #WorldADC #Biotechnology #CancerResearch #jsmePPF

Today we had the pleasure of welcoming the new Swiss ambassador, H.E. Urs Bucher, and his embassy colleagues to SOTIO Biotech ’s Prague office. Radek Spisek , Pavel Solsky and I gave our guests a tour of our lab space and presented the latest on SOTIO’s efforts to advance #cancer #research . Together with Luděk Sojka Sojka from our affiliate company SCTbio , we also visited lab space that is focused on the manufacturing of #celltherapies . SOTIO is one of the leaders in creating and promoting Czech-Swiss relations. Thank you for your visit and engaging in interesting discussion, Your Excellency! #cancerresearch #Switzerland #jsmePPF

Richard Kapsa

SOTIO will present three posters at the Society for Immunotherapy of Cancer (SITC) Meeting next month in Houston, Texas, including data supporting SOT201, a next-generation PD-1 targeting immunocytokine. Learn more details in our press release: https://bit.ly/48eWZU8 #SITC2024 #Biotechnology #DrugDevelopment #CancerResearch #jsmePPF

Our CEO, Radek Spisek , recently joined the Labiotech.eu #BeyondBiotechpodcast to discuss the pioneering developments in bispecific antibody-drug conjugates (ADCs) and their potential to revolutionize the field of #oncology . On bispecific ADCs, Radek shares: “There are good scientific reasons to believe that there are clinical situations or tumors that make sense to target [two antigens] at the same time, rather than to just go after one.” Tune in to learn more about SOTIO’s ADC platform, including SOT102, now in Phase 1/2 clinical studies in the U.S. and Europe: https://bit.ly/4eLwp7I #ADC #biotechnology #jsmePPF

Metric
Company Name	SOTIO Biotech	Autolus Therapeutics plc	Genmab A/S	Imcheck Therapeutics
Symbol		AUTL	GMAB
MSH ID	COM:SOTIO	COM:AUTOLUS	COM:GENMAB	COM:IMCHECKTHERAPEUTICS
Market	PRIVATE	STOCKS	STOCKS	PRIVATE
Sector	Healthcare & Health Services	Healthcare	Healthcare	Healthcare & Health Services
Industry	Biotechnology	Biotechnology	Biotechnology	Biotechnology
Country	CZ	GB	DK	FR
Stage	Venture Round
Employee Count		463	2.29K	51
Website	sotio.com	autolus.com	genmab.com	imchecktherapeutics.com
LinkedIn	sotio	autolus-ltd-	genmab	imcheck-therapeutics
Founders

Metric
Market Cap		1.05B	16.48B	645.43M
Enterprise Value
Monthly Web Traffic	3.94K
Web Traffic Growth	-0.39
Valuation
Raised Capital	316.57M

Metric
Revenue	1.70M	2.33B
Revenue (LTM)
Revenue (NTM)
Gross Profit	1.70M	2.30B
EBITDA	-175.53M	928.30M
Operating Income	-175.53M	753.54M
Net Income	-208.38M	616.32M
EPS	-1.20	9.44
Diluted EPS	-1.20	9.35
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin	0.55	0.99
Operating Profit Margin	-14.00	0.32
EBITDA Margin	-103.37	0.40
Net Profit Margin	-18.03	0.31
Return on Equity	-0.67	0.18
Return on Assets	-0.25	0.15
Return on Capital Employed	-0.20	0.18

SOTI

COM:SOTIO

SOTIO Biotech

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio	-6.85	28.94
P/B Ratio	6.00	4.00
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio	673.64	8.21
EV Multiple	-5.21	23.86

Metric
Days Sales Outstanding	2.77K	116.47
Days Payables Outstanding	631.58
Days Inventory Outstanding	950.75	94.14
Operating Cycle	9.97K	201.66
Cash Conversion Cycle	9.91K	-1.92K
Asset Turnover	0.01	0.49

Metric
Operating Cash Flow	-145.59M	1.05B
Free Cash Flow	-145.59M	991.89M
Cash Flow to Debt	-0.62	9.58
Operating Cash Flow/Sales	-11.71	0.45
Free Cash Flow Yield	-0.13	0.05

Metric
Cash & Equivalents	239.57M	2.11B
Accounts Receivable		112.87M
Inventory	-24.54M	8.07M
Goodwill
Debt to Capitalization	0.32	0.03
Debt to Assets	0.13	0.02
Current Ratio	8.21	11.38
Quick Ratio	18.50	13.32

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue	2.05
R&D to Revenue	24.90	0.43
SG&A to Revenue	6.96